REVIEW
197  Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside

MINIREVIEWS
216  Latest therapeutic target for gastric cancer: Anthrax toxin receptor 1
Sun KR, Lv HF, Chen BB, Nie CY, Zhao J, Chen XB
223  Primary malignant vascular tumors of the liver in children: Angiosarcoma and epithelioid hemangioendothelioma
Bannoura S, Putra J
231  Nanotechnology and pancreatic cancer management: State of the art and further perspectives
Caputo D, Pozzi D, Farolfi T, Passa R, Coppola R, Caracciolo G
238  Colorectal cancer screening in the COVID-19 era

ORIGINAL ARTICLE
Retrospective Study
252  Predictive factors for early distant metastasis after neoadjuvant chemoradiotherapy in locally advanced rectal cancer
Park H
265  Expression profiles of gastric cancer molecular subtypes in remnant tumors
Ramos MFKP, Pereira MA, Cardili L, de Mello ES, Ribeiro Jr U, Zilberstein B, Cecconello I

Observational Study
279  Multinational survey on the preferred approach to management of Barrett’s esophagus in the Asia-Pacific region

295  Clinical efficacy and safety of second line and salvage afiblercept for advanced colorectal cancer in Akita prefecture

CASE REPORT
305  Crohn’s disease with infliximab treatment complicated by rapidly progressing colorectal cancer: A case report
Xiao L, Sun L, Zhao K, Pan YS
ABOUT COVER
Editorial Board Member of World Journal of Gastrointestinal Oncology, Asfar Sohail Azmi, BSc, MSc, PhD, Associate Professor, Director, Department of Oncology, Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI 48201, United States. azmia@karmanos.org

AIMS AND SCOPE
The primary aim of World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING
The WJGO is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, PubMed Central, and Scopus. The 2020 edition of Journal Citation Reports® cites the 2019 impact factor (IF) for WJGO as 2.898; IF without journal self-cites: 2.880; 5-year IF: 3.316; Ranking: 143 among 244 journals in oncology; Quartile category: Q3; Ranking: 55 among 88 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO’s CiteScore for 2019 is 2.0 and Scopus CiteScore rank 2019: Gastroenterology is 86/137.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Jia-Hui Li; Production Department Director: Xiang Li; Editorial Office Director: Ya-Juan Ma.

NAME OF JOURNAL
World Journal of Gastrointestinal Oncology

ISSN
ISSN 1948-5204 (online)

LAUNCH DATE
February 15, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Rosa M Jimenez Rodriguez, Pashtoon Kasi, Monjur Ahmed, Florin Burada

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
April 15, 2021

COPYRIGHT
© 2021 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/GerInfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Primary malignant vascular tumors of the liver in children: Angiosarcoma and epithelioid hemangioendothelioma

Sami Bannoura, Juan Putra

ORCID number: Sami Bannoura 0000-0001-9656-2961; Juan Putra 0000-0002-3487-4641.

Author contributions: Bannoura S reviewed the literature and drafted the manuscript; Putra J reviewed the literature, acquired the histological images, and edited the final version of the manuscript; both authors approved the final version to be published.

Conflict-of-interest statement: The authors have nothing to disclose.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Specialty type: Pathology

Country/Territory of origin: Canada

Sami Bannoura, Juan Putra, Department of Paediatric Laboratory Medicine, Hospital for Sick Children, 555 University Ave, Toronto M5G 1X8, Ontario, Canada

Corresponding author: Juan Putra, MD, Assistant Professor, Staff Physician, Department of Paediatric Laboratory Medicine, Hospital for Sick Children, 555 University Ave, Toronto M5G 1X8, Ontario, Canada. juan.putra@sickkids.ca

Abstract

Primary malignant vascular neoplasms of the liver, angiosarcoma and epithelioid hemangioendothelioma, are extremely rare entities in the pediatric population. International Society for the Study of Vascular Anomalies classification system is recommended for the pathologic diagnosis of hepatic vascular lesions in this age group. In this article, we highlight the clinicopathologic characteristics of hepatic angiosarcoma and epithelioid hemangioendothelioma in the pediatric population. Hepatic angiosarcoma in children shows a slight female predominance with an average age of 40 mo at diagnosis. The distinct histologic features include whorls of atypical spindled cells and eosinophilic globules, in addition to the general findings of angiosarcoma. Histologic diagnosis of pediatric hepatic angiosarcoma is not always straightforward, and the diagnostic challenges are discussed in the article. Hepatic epithelioid hemangioendothelioma also demonstrates a female predominance, but is more commonly identified in adolescents (median age at diagnosis: 12 years). Histologically, the lesion is characterized by epithelioid cells and occasional intracytoplasmic lumina with a background of fibromyxoid stroma. While WWTR1-CAMTA1 and YAP1-TFE3 fusions have been associated with epithelioid hemangioendothelioma, there are currently no known signature genetic alterations seen in pediatric hepatic angiosarcoma. Advancement in molecular pathology, particularly for pediatric hepatic angiosarcoma, is necessary for a better understanding of the disease biology, diagnosis, and development of targeted therapies.

Key Words: Pediatric; Hepatic angiosarcoma; Epithelioid hemangioendothelioma; Infantile hemangioma; Liver tumor; Molecular genetics

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
**INTRODUCTION**

Malignant liver tumors are rare in the pediatric population, comprising approximately 1.1% of all childhood malignancies in the United States\[1\]. The most common malignant hepatic tumors in children are those of epithelial origin (hepatoblastoma and hepatocellular carcinoma). Meanwhile, the less frequent malignant neoplasms of mesenchymal origin include undifferentiated embryonal sarcoma, rhabdomyosarcoma, and malignant vascular tumors\[2,3\]. Hepatic vascular lesions in children, both benign and malignant, may pose diagnostic challenges because of the confusing terminology and their overlapping clinical, radiologic, and pathologic features\[4\].

The use of previous terminology for hepatic vascular lesions in children (types 1 and 2 hemangioendothelioma) is discouraged, as these diagnostic terms have led to confusion in diagnosis and management\[5\]. We recommend the use of classification by the International Society for the Study of Vascular Anomalies (ISSVA) instead. This classification system was developed to allow a better understanding of the biology and genetics of vascular lesions and serves as a guide to clinicians, pathologists, and researchers\[6\]. For the complete list of vascular anomalies (updated in 2018), please review the ISSVA document (https://www.issva.org/UserFiles/file/ISSVA-Classification-2018.pdf).

Based on the biologic behavior, primary hepatic vascular tumors can be grouped into benign, borderline, and malignant lesions. Christison-Lagay et al\[7\] classify benign hepatic vascular lesions (hemangiomas) according to their clinical presentations into focal, multifocal, and diffuse hepatic hemangiomas. Histologically, focal hepatic hemangiomas are in keeping with rapidly involuting congenital hemangiomas. Meanwhile, multifocal and diffuse hepatic hemangiomas correspond to infantile hemangiomas. Kaposi sarcoma, primarily seen in immunocompromised patients, represents borderline vascular tumors of the liver. Hepatic malignant vascular lesions include angiosarcoma and epithelioid hemangioendothelioma; in this article, we will review the clinicopathologic characteristics of these two entities with a focus on the pediatric population.

**HEPATIC ANGIOSARCOMA**

Angiosarcoma is a malignant vascular neoplasm that recapitulates morphological and immunohistochemical features of endothelial cells. The lesion is more commonly seen in elderly men, and usually involves the cutaneous and deep soft tissue\[8\]. In the pediatric population, mediastinum is a frequent site of involvement\[9\]. Pediatric hepatic angiosarcoma is exceptionally rare and has only been described in case reports or small case series\[10\]. In this age group, hepatic angiosarcoma shows a slight female predominance and the average age of presentation is 40 mo\[9\]. The pathogenesis of hepatic angiosarcoma in children is unclear. The association between angiosarcoma
and exposure to thorotrast, vinyl chloride, androgenic and anabolic steroids, oral contraceptives, and diethylstilbestrol, as described in adults, is usually not identified in children since it requires several years of environmental exposure prior to tumor detection\(^\text{[8,9]}\). Only one case of pediatric hepatic angiosarcoma has been associated with arsenic exposure\(^\text{[10]}\). Moreover, there is no recognized syndromic or genetic association. However, pediatric hepatic angiosarcoma has been associated with different conditions, such as multiple cutaneous infantile hemangiomas\(^\text{[11,12]}\), cutaneous mixed vascular malformations\(^\text{[13]}\), and dyskeratosis congenita\(^\text{[14]}\).

Children with hepatic angiosarcoma usually present with abdominal pain and distension due to rapid liver enlargement. Metastatic disease is common at diagnosis, particularly to the lungs\(^\text{[15,16]}\). The tumor also occasionally ruptures and leads to hemoperitoneum\(^\text{[17,18]}\). Other signs and symptoms include jaundice, vomiting, fever, dyspnea, and anemia\(^\text{[19]}\). The imaging features of hepatic angiosarcoma are variable and may be mistaken for benign entities such as infantile hemangiom\(^\text{a[20]}\). On ultrasound, the lesion may present as solitary or multifocal, heterogeneous hypoechoic to isoechoic nodules. Computed tomography scan often demonstrates peripheral nodular and irregular hypervascularity with arterial hemorrhage. Moreover, magnetic resonance imaging generally shows marked heterogeneity on T2-weighted images and all phases of post-contrast images, and bizarre progressive filling (instead of centripetal)\(^\text{[21]}\). Because of the nonspecific clinical and imaging findings, tissue examination remains the gold standard for the diagnosis of hepatic angiosarcoma.

Macroscopically, hepatic angiosarcoma generally presents a large solitary lesion or multiple nodules, either separate or coalescing, sometimes with infiltrative borders and possibly replacing the hepatic parenchyma. The cut surface can be fleshy, cystic, and variegated with areas of hemorrhage and necrosis\(^\text{[22,23]}\). Histologically, pediatric hepatic angiosarcoma may be indistinguishable from adult angiosarcoma.

The lesional cells may show different growth patterns: vasoformative, epithelioid/spindled, peliotic, and sinusoidal growth\(^\text{[24]}\). These cells range from eosinophilic and spindled to markedly pleomorphic with high nuclear-to-cytoplasmic ratio, hyperchromatic nuclei, prominent nucleoli, and increased mitotic activity\(^\text{[25,26]}\). Pediatric hepatic angiosarcomas (Figure 1) usually has a characteristic component of whorls of atypical spindled cells (glomeruloid bodies) and periodic acid-Schiff-positive diastase-resistant cytoplasmic eosinophilic globules\(^\text{[27,28]}\). Intratumoral entrapment of native structures, such as hepatocytes and bile ducts, is occasionally identified. By immunohistochemistry, the neoplastic cells are positive for endothelial markers (CD31, CD34, factor VIII, FLI-1, and ERG). In addition, they are occasionally immunoreactive for podoplanin\(^\text{[29]}\) and GLUT-1\(^\text{[30]}\), markers for lymphatic differentiation and infantile hemangioma, respectively.

Pathologic diagnosis of pediatric hepatic angiosarcoma is not always straightforward. The lesion can have regions of small channels with bland appearing endothelium, mimicking infantile hemangioma. Potential for malignant transformation of benign vascular tumors and focal GLUT-1 positivity also make the distinction between hepatic angiosarcoma and infantile hemangioma challenging\(^\text{[31,32]}\).

Moreover, a definitive diagnosis is sometimes difficult to render because of limited tissue or sampling. Hepatic angiosarcoma should be considered in cases of infantile hemangiomas diagnosed in patients greater than one year of age. A malignant diagnosis should also be suspected in infantile hemangiomas which are resistant to treatment, recur, or do not regress within two years of age\(^\text{[33,34]}\). Hepatic angiosarcoma showing markedly atypical cells should be distinguished from other high-grade lesions, such as undifferentiated embryonal sarcoma, rhabdomyosarcoma, and malignant rhabdoid tumor. Immunohistochemistry is usually helpful to exclude these differential diagnoses. In adults, hepatic angiosarcoma has been reported concomitantly with mesenchymal hamartoma with or without undifferentiated embryonal sarcoma component\(^\text{[35,36]}\). This association, however, has not been observed in pediatric patients. Finally, the possibility of metastatic disease should be ruled out radiologically, as secondary involvement of the liver by angiosarcoma of various primary sites (skin, spleen, and mesentery) has been reported in children\(^\text{[37,38]}\).

Antonescu et al\(^\text{[39]}\) reported upregulation of vascular-specific receptor tyrosine kinases in primary and radiation-induced angiosarcomas. Meanwhile, MYC amplification is exclusively observed in radiation-induced and chronic lymphedema-associated angiosarcomas\(^\text{[40]}\). In addition, a subset of angiosarcomas in young adults is associated with CIC gene abnormalities, which show an inferior outcome\(^\text{[41]}\). There are, however, no known signature molecular alterations in pediatric hepatic angiosarcoma. Marks et al\(^\text{[42]}\) reported a novel gene fusion of ROS1-GOPC in hepatic angiosarcoma of a 50-year-old woman. Although the finding has not been confirmed by other studies, it has a potential clinical significance because of the established anti-cancer activity of
tyrosine kinase inhibitors in tumors with ROS1 rearrangements.

Pediatric hepatic angiosarcoma has a dismal prognosis, with a 5-year overall survival less than 30%. The majority of patients succumb to disease within 12 mo after diagnosis. Currently, there is no established consensus on management of pediatric hepatic angiosarcoma. Management generally depends on the extent of disease and usually involves the combination of chemotherapy, neoadjuvant or adjuvant, with surgical resection (when possible). Other treatment options with limited success include embolization, radiation, liver transplantation, and targeted therapy, such as mammalian target of rapamycin and vascular-specific receptor tyrosine kinase inhibitors.

HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA

Epithelioid hemangioendothelioma is an exceedingly rare tumor of vascular endothelial origin. It is more commonly seen in adult females (median age of onset is > 30 years) and has an estimated prevalence of less than 1 in 1000000. In the pediatric population, it usually presents as a multifocal disease with multiorgan involvement, most frequently involving liver, lungs, bone and, soft tissue. Pediatric hepatic epithelioid hemangioendothelioma shows a female predominance with a median age at diagnosis of 12 years. The etiology of epithelioid hemangioendothelioma is unclear, and there are no established syndromic or genetic associations in children.

Approximately 25% of patients with hepatic epithelioid hemangioendothelioma are asymptomatic, while symptomatic patients usually show abdominal pain, weight loss, and a palpable mass. On rare occasions, hepatic epithelioid hemangioendothelioma may present as veno-occlusive disease or Budd-Chiari syndrome. Pediatric epithelioid hemangioendothelioma has characteristic radiologic findings including peripheral location of lesions, subcapsular retraction, and the “lollipop sign”. The latter represents a hepatic or portal vein tapering at the periphery of a well-defined lesion seen on computerized tomography and magnetic resonance imaging. Macroscopic examination of hepatic epithelioid hemangioendothelioma shows firm, ill-defined, and sometimes confluent nodules with infiltrative borders. The lesion usually involves both hepatic lobes with predominant peripheral or subcapsular
growth pattern. Histologically, the lesion is characterized by cords and nests of epithelioid cells in a variable fibromyxoid stroma (Figure 2). The lesion often appears hypocellular and deceptively bland. The neoplastic cells have moderate amounts of eosinophilic cytoplasm, round nuclei, and inconspicuous nucleoli. Intracytoplasmic vacuoles/Lumina are occasionally seen. There is minimal cytologic atypia with low mitotic activity. The neoplastic cells usually grow along vascular structures and infiltrate hepatic sinusoids, which lead to atrophy and replacement of hepatocytes. The portal tracts and hepatic venules are usually intact despite destruction of the hepatic plates. Older lesions may demonstrate sclerosis, necrosis, and/or calcification. By immunohistochemistry, the neoplastic cells show expression of endothelial markers including CD31, CD34, ERG, FLI-1, factor VIII, and lymphatic marker podoplanin (D2-40). The lesional cells also demonstrate variable expression for cytokeratin and smooth muscle actin. The stroma shows variable staining with mucicarmine, para-aminosalicylic acid in early lesions, and Masson trichrome in older lesions. The histologic differential diagnoses for hepatic epithelioid hemangioendothelioma include angiosarcoma, cholangiocarcinoma, metastatic carcinoma, and sclerosing hepatocellular carcinoma. Important to note that these entities are mostly seen in adult patients.

Epithelioid hemangioendothelioma is associated with t (1; 3) (p36; q25) and t (11; X) (q13; p11) translocations, which correspond to WWTR1-CAMTA1 and YAPI-TFE3 gene fusions, respectively. The WWTR1-CAMTA1 translocation results in a fusion protein which allows for a TAZ-like transcriptional program and leads to oncogenesis. Immunochemistry for CAMTA-1 and TFE3 is also useful to confirm these gene fusions. The WWTR1-CAMTA1 and YAPI-TFE3 gene fusions are identified in 90% and 10% of epithelioid hemangioendothelioma cases, respectively. Hepatic epithelioid hemangioendothelioma demonstrates a variable clinical course, with uncertain long-term prognosis. In general, it is considered less aggressive than hepatic angiosarcoma. The presence of effusions, tumor size > 3 cm, and high mitotic index (> 3 mitoses/50 high power fields) have been associated with unfavorable outcomes. Moreover, Rosenbaum et al. reported that patients with WWTR1-CAMTA1 fusion have a less favorable outcome compared with the YAPI-TFE3 fusion, with 5-year overall survival rates of 59% and 86%, respectively. There are currently no established standardized management protocols for the pediatric age group; surgical resection is considered the mainstay of treatment for localized disease. In advanced disease, management is more variable, such as observation, medical therapy, and liver transplantation. Medical therapy includes standard chemotherapy and targeted agents, such as anti-vascular endothelial growth factor antibody (e.g., bevacizumab) and mammalian target of rapamycin inhibitor (e.g., sirolimus).

**CONCLUSION**

Malignant hepatic vascular neoplasms in the pediatric population, including angiosarcoma and epithelioid hemangioendothelioma, are rarely encountered. Table 1 summarizes the clinico-pathological characteristics of these lesions. We recommend the use of the ISSVA classification system for the pathologic diagnosis of hepatic vascular lesions in children. Currently, there are no established management guidelines for both pediatric hepatic angiosarcoma and epithelioid hemangioendothelioma because of their rarity and heterogeneous presentations. Advancement in molecular pathology, particularly for pediatric hepatic angiosarcoma, could potentially lead to a better understanding of the disease biology, diagnosis, and development of targeted therapies.
**Table 1 Clinicopathologic characteristics of pediatric hepatic angiosarcoma and epithelioid hemangioendothelioma**

<table>
<thead>
<tr>
<th></th>
<th>Angiosarcoma</th>
<th>Epithelioid hemangioendothelioma</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
<td>Female predominance; mean age at diagnosis: 40 mo</td>
<td>Female predominance; median age at diagnosis: 12 yr</td>
</tr>
<tr>
<td><strong>Clinical presentation</strong></td>
<td>Abdominal pain, and distension due to rapid liver enlargement. Lung metastasis is common</td>
<td>Mostly present with multiorgan involvement, most frequently involving liver, lungs, bone and soft tissue</td>
</tr>
<tr>
<td><strong>Associated conditions</strong></td>
<td>Cutaneous and hepatic infantile hemangiomas, cutaneous vascular malformations, dyskeratosis congenita</td>
<td>None reported</td>
</tr>
<tr>
<td><strong>Molecular</strong></td>
<td>Unknown ([ROS1-GOPC fusion reported in an adult hepatic angiosarcoma][29])</td>
<td>WWTR1-CAMTA1 fusion (90%) YAP1-TFE3 fusion (10%)</td>
</tr>
<tr>
<td><strong>Histology</strong></td>
<td>Well-formed, anastomosing vessels to more solid areas composed of pleomorphic spindle cells. Hypercellular whorls of spindled cells (glomeruloid bodies). Intracytoplasmic eosinophilic globules (periodic acid-Schiff -positive and diastase-resistant)</td>
<td>Cords and nests of epithelioid cells in a variable fibromyxoid stroma. Occasional intracytoplasmic vacuoles/lumina. Minimal cytologic atypia with low mitotic rates</td>
</tr>
<tr>
<td><strong>Immunohistochemistry</strong></td>
<td>CD31, CD34, factor VIII, FLI-1, ERG, occasionally podoplanin and GLUT-1</td>
<td>CD31, CD34, factor VIII, FLI-1, ERG, variable podoplanin, smooth muscle actin and keratin</td>
</tr>
</tbody>
</table>

**Figure 2** Pediatric hepatic epithelioid hemangioendothelioma. A: Hypocellular epithelioid cells embedded in fibrotic stroma (right); entrapped hepatocytes with cholestasis are noted on the left (hematoxylin-eosin staining, 4 ×); B: High power view of the lesion demonstrates scattered atypical cells (arrowhead) with occasional intracytoplasmic lumen formation (arrow) (Hematoxylin-eosin staining, 20 ×); C: The neoplastic cells are immunoreactive for CD31 (20 ×); D: The neoplastic cells are immunoreactive for CK7 (20 ×).

**REFERENCES**


